Rein Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Rein Therapeutics, Inc. (formerly Aileron Therapeutics, Inc.) is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications with significant unmet medical needs. The company's lead product candidate is LTI-03, a novel synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, currently in Phase 2 clinical development for idiopathic pulmonary fibrosis (IPF). Its second clinical asset, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions (LPE). Rein Therapeutics was established through a reverse merger with Lung Therapeutics, Inc. in October 2023 and subsequently rebranded from Aileron to Rein Therapeutics in January 2025.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of lead candidate LTI-03, an inhaled synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, for the treatment of idiopathic pulmonary fibrosis (IPF).
Expected impact: Establish safety, tolerability, and efficacy (measured by forced vital capacity and high-resolution CT imaging) to support progression to Phase 3 development.
Indefinitely pausing clinical development of secondary asset LTI-01 (for loculated pleural effusions) and preclinical programs in cystic fibrosis and Cav1 systemic fibrosis to concentrate all financial and operational resources on the LTI-03 IPF program.
Expected impact: Significantly reduces operational cash burn, extending the company's cash runway into 2028.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Integrating Qureight's deep-learning image analytics platform into the Phase 2 RENEW trial to provide precise, quantitative measurements of lung structure, vascularity, and airway compartments, correlating volumetric changes with LTI-03 biomarker activity.
Terms: Terms not publicly disclosed.
Partnering with IQVIA to manage global patient screening, recruitment, and enrollment operations across up to 50 clinical sites for the Phase 2 RENEW trial of LTI-03.
Terms: Terms not publicly disclosed.